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Abstract: Curcumin is an antimalarial compound easy to obtain and inexpensive, having shown
little toxicity across a diverse population. However, the clinical use of this interesting polyphenol
has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid
metabolism. In this study, we have used the anionic copolymer Eudragit® S100 to assemble liposomes
incorporating curcumin and containing either hyaluronan (Eudragit-hyaluronan liposomes) or
the water-soluble dextrin Nutriose® FM06 (Eudragit-nutriosomes). Upon oral administration of
the rehydrated freeze-dried nanosystems administered at 25/75 mg curcumin·kg−1·day−1, only
Eudragit-nutriosomes improved the in vivo antimalarial activity of curcumin in a dose-dependent
manner, by enhancing the survival of all Plasmodium yoelii-infected mice up to 11/11 days, as
compared to 6/7 days upon administration of an equal dose of the free compound. On the other hand,
animals treated with curcumin incorporated in Eudragit-hyaluronan liposomes did not live longer
than the controls, a result consistent with the lower stability of this formulation after reconstitution.
Polymer-lipid nanovesicles hold promise for their development into systems for the oral delivery of
curcumin-based antimalarial therapies.
Keywords: malaria; curcumin; nanomedicine; oral administration; lipid nanovesicles; Eudragit;
Nutriose; hyaluronan; Plasmodium yoelii
1. Introduction
The polyphenolic compound curcumin (Figure 1) has been described to inhibit the in vitro growth
of chloroquine-resistant Plasmodium falciparum in a dose-dependent manner with a half-maximal
inhibitory concentration (IC50) between 5–18 µM [1,2]. In vivo, oral administration of curcumin to
mice infected with the murine malaria parasite Plasmodium berghei reduced blood parasitemia by 80%
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to 90% and significantly enhanced survival. Curcumin was able to delay the death of animals by about
10 days and prevent cerebral malaria, the most severe and rapidly fatal neurological complication of
the disease [3–6]. In addition to having a direct antiplasmodial effect, curcumin has also been described
to prime the immune system against P. berghei [4]. In order to expand this potential as antimalarial,
curcumin derivatives have been synthesized and some of them demonstrated an improved in vitro
IC50 around 400 nM [7]. This inexpensive molecule is easily isolated from rhizome extracts of turmeric
(Curcuma longa) and has shown low toxicity in animals [8] and humans [9], even when used at high
doses: as much as 8 g/day administered for three months to cancer patients on trial did not exhibit
toxic side effects [10]. Despite these promising results, the clinical use of curcumin is often limited by
its extremely reduced aqueous solubility and high tissue distribution [11]. Low serum and tissue levels
of curcumin are observed regardless of the route of administration due to extensive intestinal and
hepatic metabolism along with rapid elimination, which contribute to restrain its bioavailability [12–15].
When administered orally, curcumin undergoes conjugation leading to the formation of curcumin
glucuronide and sulphates in the intestinal wall [16], which together with its strong interaction with
bile salts contribute to reduce its absorption [17]. In addition, curcumin is a highly unstable molecule,
sensitive to various conditions like light, pH and temperature [18,19].
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Figure 1. Chemical structure of curcumin. 
Attempts to overcome these shortcomings of curcumin have contemplated its incorporation in 
different types of nanoparticles [20–24]. The oral administration of drugs in nanocarriers represents 
an attractive strategy because it can ensure local delivery and accumulation in the intestines, thus 
improving systemic bioavailability [25–27]. Binding of curcumin to chitosan nanoparticles increased 
its chemical stability and when fed to mice in this nanoparticulate formulation, it significantly 
prolonged animal survival when compared to the free compound [28]. While treatment of infected 
mice at low parasitemia (less than 2%) with curcumin-bound chitosan nanoparticles resulted in 
survival of all the animals, if the treatment were started at higher parasite loads survival was not 
100% [28]. Among the different nanosystems, liposomes have been widely employed due to their 
safety and versatility. The incorporation of curcumin in phospholipid vesicles can modulate its 
interaction with the gut mucosa but these formulations cannot ensure drug stability in the 
gastrointestinal environment due to the phospholipid degradation under such conditions [29,30]. 
Electrostatic interactions with external ions play an important role in the stability of liposomes, as 
they can cause an alteration of the structure and size, with possible rupture and content leakage 
[31,32]. To overcome this limitation, the appropriate combination of phospholipids with 
gastro-resistant polymers and/or fibres can offer protection to the vesicles, resulting in an enhanced 
local and systemic bioavailability of the payload. Phospholipid vesicles have been developed 
incorporating different natural polymers, such as chitosan, sodium alginate, xanthan gum, gelatin, 
pectin and cellulose ethers [31,33,34]. Liposomes were also coated with the methacrylic acid 
copolymer Eudragit®  S100 to improve vesicle stability [35], and curcumin-Eudragit solid dispersions 
[25] have been proposed as treatment for gastric ulcer [36] and for colon-specific drug delivery [37]. 
Through an environmentally friendly preparation method previously employed to produce 
hyalurosomes [38], Eudragit was combined with hyaluronan to protect liposomes from gastric pH 
and promote curcumin deposition in the intestines [39]. Liposomes prepared without the polymers 
were not suitable for pharmaceutical applications, as they were large in size (diameter ≥700 nm), 
polydispersed (polydispersity index ≥0.70) and unstable, displaying curcumin precipitation in a 
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Attempts to overcome these shortcomings of curcumin have contemplated its incorporation in
different types of nanoparticles [20–24]. The oral administration of drugs in nanocarriers represents
an attractive strategy because it can ensure local delivery and accumulation in the intestines, thus
improving systemic bioavailability [25–27]. Binding of curcumin to chitosan nanoparticles increased its
chemical stability and when fed to mice in this nanoparticulate formulation, it significantly prolonged
animal survival when compared to the free compound [28]. While treatment of infected mice at low
parasitemia (less than 2%) with curcumin-bound chitosan nanoparticles resulted in survival of all the
animals, if the treatment were started at higher parasite loads survival was not 100% [28]. Among
the different nanosystems, liposomes have been widely employed due to their safety and versatility.
The incorporation of curcumin in phospholipid vesicles can modulate its interaction with the gut
mucosa but these formulations cannot ensure drug stability in the gastrointestinal environment due to
the phospholipid degradation under such conditions [29,30]. Electrostatic interactions with external
ions play an important role in the stability of liposomes, as they can cause an alteration of the structure
and size, with possible rupture and content leakage [31,32]. To overcome this limitation, the appropriate
combination of phospholipids with gastro-resistant polymers and/or fibres can offer protection to
the vesicles, resulting in an enhanced local and systemic bioavailability of the payload. Phospholipid
vesicles have been developed incorporating different natural polymers, such as chitosan, sodium
alginate, xanthan gum, gelatin, pectin and cellulose ethers [31,33,34]. Liposomes were also coated with
the methacrylic acid copolymer Eudragit® S100 to improve vesicle stability [35], and curcumin-Eudragit
solid dispersions [25] have been proposed as treatment for gastric ulcer [36] and for colon-specific
drug delivery [37]. Through an environmentally friendly preparation method previously employed to
produce hyalurosomes [38], Eudragit was combined with hyaluronan to protect liposomes from gastric
pH and promote curcumin deposition in the intestines [39]. Liposomes prepared without the polymers
were not suitable for pharmaceutical applications, as they were large in size (diameter ≥ 700 nm),
polydispersed (polydispersity index ≥ 0.70) and unstable, displaying curcumin precipitation in a
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short time. Alternatively, new phospholipid nanovesicles designed for intestinal delivery were
developed by simultaneously loading the water-soluble dextrin Nutriose® FM06 and curcumin.
These innovative vesicles, termed nutriosomes, improved the local and systemic bioavailability and
the biodistribution of curcumin upon oral administration [40]. Of note, both Eudragit-hyaluronan
liposomes and nutriosomes were freeze-dried to preserve the carrier’s performance and improve their
stability on storage, which usually represents one of the major limitations to commercial applications.
In the present work, we combined Eudragit with hyaluronan or Nutriose and phospholipids,
thus producing Eudragit-hyaluronan liposomes and Eudragit-nutriosomes, respectively, to protect
curcumin from degradation and ameliorate its efficacy. Because these properties are highly desirable
for the currently required oral administration of drugs in non-complicated malaria, we have explored
the capacity of these two nanovesicles to improve the antiplasmodial activity of curcumin in an in vivo
model of the disease.
2. Results
2.1. Nanovesicle Characterization
Eudragit-hyaluronan liposomes and Eudragit-nutriosomes were prepared according to the
compositions reported in Table 1.
Table 1. Composition (expressed as mg/mL of water in rehydrated samples) of Eudragit-hyaluronan
liposomes and Eudragit-nutriosomes.
Nanovesicles P90G Curcumin Hyaluronan Eudragit Nutriose
Eudragit-hyaluronan liposomes 180 10 3.75 12.5 –
Eudragit-nutriosomes 180 10 – 12.5 75
The mean diameter of freshly prepared (before freeze-drying) Eudragit-hyaluronan liposomes
and Eudragit-nutriosomes was approximately 1100 nm and the polydispersity index (PI) was >0.6
(Table 2). After freeze-drying, the samples were re-hydrated with water and sonicated, resulting
in the production of much smaller vesicles with narrower size distribution (~150 nm and PI < 0.3).
The zeta potential was not affected by the freeze-drying process: values were around −30 mV for both
formulations. Eudragit-hyaluronan liposomes and Eudragit-nutriosomes showed the same values of
entrapment efficiency (79.3 ± 5.6% and 81 ± 8.7%, respectively).
Table 2. Mean diameter (MD), polydispersity index (PI) and zeta potential (ZP) of curcumin-loaded
Eudragit-hyaluronan liposomes and Eudragit-nutriosomes. Each value represents the mean± standard
deviation, n ≥ 3.
Treatment Nanovesicles MD (nm) PI ZP (mV)
Before
freeze-drying
Eudragit-hyaluronan liposomes 1113 ± 109 0.75 ± 0.09 −39.9 ± 2.5
Eudragit-nutriosomes 1141 ± 96 0.61 ± 0.11 −35.8 ± 3.1
After freeze-drying
and sonication
Eudragit-hyaluronan liposomes 156 ± 12 0.29 ± 0.03 −36.2 ± 2.6
Eudragit-nutriosomes 151 ± 8 0.24 ± 0.05 −33.7 ± 3.7
Cryo-transmission electron microscopy (cryo-TEM) analysis revealed for rehydrated
Eudragit-nutriosomes incorporating curcumin the presence of well-formed vesicles with the expected
size around 150 nm in diameter [40] (Figure 2A–C). On the other hand, curcumin-containing
Eudragit-hyaluronan liposomes were slightly larger in size (Figure 2D), but their cryo-TEM images
revealed the presence of abundant disassembled vesicles and membrane fragments, suggesting a
certain instability of these structures (Figure 2E).
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Figure 2. Cryo-TEM analysis of rehydrated curcumin-incorporating (A–C) Eudragit-nutriosomes and
(D,E) Eudragit-hyaluronan liposomes. Scale bars represent 200 nm.
2.2. Vesicle Behavior in Gastrointestinal Fluids
Since pH and ionic strength variations along the gastrointestinal tract can affect vesicle
performance, the behaviour of Eudragit-hyaluronan liposomes and Eudragit-nutriosomes under
conditions mimicking gastric and intestinal media was evaluated. To this aim, two high ionic
strength solutions at pH 1.2 and pH 7.0 were assayed. After 2 h at acidic pH, an increase in size
and polydispersity was observed for Eudragit-hyaluronan liposomes (>200 nm, PI > 0.3; Table 3),
while Eudragit-nutriosomes showed no sign of physical alteration, as demonstrated by the fact that
their size was essentially unchanged (~150 nm, PI ~ 0.2). An inversion of the zeta potential to around
+13 mV was detected for both formulations, due to the pr sence of H+ in the acidic medium. Similar
results were observed after 6 h of incubation at pH 7.0, confirming that Eudragit-nutriosomes were
more stable than Eudragit-hyaluronan liposomes, as the structure of the former was preserved despite
pH variation and ionic strength.
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Table 3. Mean diameter (MD), polydispersity index (PI) and zeta potential (ZP) of rehydrated
curcumin-loaded Eudragit-hyaluronan liposomes and Eudragit-nutriosomes diluted and incubated at
37 ◦C in acidic solution (pH 1.2) for 2 h or in neutral solution (pH 7.0) for 6 h, both containing 0.3 M
NaCl. The measurements were carried out immediately after dilution (t0) at 25 and 37 ◦C, and after 2
(t2) or 6 h (t6) of incubation at 37 ◦C. Mean values of ≥3 replicates ± SD are reported.
pH Nanovesicles Time, Temperature MD (nm) PI ZP (mV)
pH 1.2
Eudragit-hyaluronan liposomes
t0, 25 ◦C 138 ± 12 0.32 ± 0.05 +12.5 ± 0.4
t0, 37 ◦C 144 ± 28 0.40 ± 0.09 +14.0 ± 0.6
t2, 37 ◦C 215 ± 26 0.35 ± 0.09 +12.6 ± 0.9
Eudragit-nutriosomes
t0, 25 ◦C 144 ± 10 0.21 ± 0.03 +14.1 ± 0.6
t0, 37 ◦C 145 ± 8 0.22 ± 0.08 +14.7 ± 0.7
t2, 37 ◦C 142 ± 8 0.21 ± 0.06 +13.8 ± 0.6
pH 7.0
Eudragit-hyaluronan liposomes
t0, 25 ◦C 167 ± 6 0.27 ± 0.04 −6.0 ± 5.2
t0, 37 ◦C 226 ± 11 0.26 ± 0.02 −6.0 ± 4.5
t6, 37 ◦C 193 ± 8 0.23 ± 0.01 −6.2 ± 3.6
Eudragit-nutriosomes
t0, 25 ◦C 148 ± 4 0.22 ± 0.02 −2.4 ± 0.3
t0, 37 ◦C 155 ± 7 0.23 ± 0.05 −1.1 ± 0.5
t6, 37 ◦C 160 ± 4 0.23 ± 0.04 −3.0 ± 0.7
2.3. In Vivo Antimalarial Activity of Orally Administered Curcumin
Free curcumin administered orally at either 25 or 75 mg·kg−1·day−1 to mice infected with the
lethal murine malaria parasite Plasmodium yoelii yoelii 17XL did not have a curative effect on the
animals, which died at day 6 or 7 after infection, similarly to untreated controls (Figure 3). The same
amount of curcumin incorporated in Eudragit-hyaluronan liposomes did not improve significantly this
result. On the other hand, identically administered curcumin incorporated in Eudragit-nutriosomes
was able to increase mouse viability in a dose-dependent manner. At both 25 and 75 mg·kg−1·day−1,
all Eudragit-nutriosome-curcumin-treated mice lived longer than free curcumin controls, with two
animals surviving until day 11 post-infection. Because polyphenol entrapment efficiency in the
nanoformulated preparations was about 80%, the performance of the nanocarriers is underestimated
due to the presence in these samples of about 20% of non-incorporated curcumin.
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Figure 3. In vivo antimalarial activity of orally administered curcumin. Representative microscope
images of blood smears from (A) non-infected and (B) P. yoelii-infected mice. (C) Kaplan-Meier plot for
the in vivo assay of the effect on P. yoelii-infected mice (n = 3 animals/sample) of free or incorporated
curcumin administered orally at 25 and 75 mg·kg−1·day−1.
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Assuming a homogeneous distribution of the administered formulations throughout mouse
tissues, the highest concentration assayed did not exhibit hemolytic activity (Figure 4).
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3. Discussion
Because of their biocompatibility and physicochemical diversity, lipids offer vast opportunities in
nanosystems for oral drug delivery [41]. When applied for the administration of poorly water-soluble
drugs, liposomes enhance drug solubilization by creating a lipophilic environment and acting as a
shelter that protects incorporated sensitive active ingredients from direct interaction with the aggressive
gastrointestinal tract fluids. However, maximum advantages from lipid nanocarriers can only be
obtained if they survive the transit through the acidic gastric environment. The dilution in the gastric
fluid and the enzymatic breakdown of lipids may result in changes in the composition and structure of
the nanocarriers, which leads to the unwanted burst drug release [42]. In comparison with lipid-based
nanosystems, polymeric nanovessels are generally stable during gastrointestinal tract transit [43], and
advances in polymer chemistry enable exquisite control over their nanoarchitecture and biophysical
properties, which facilitates controlled drug delivery [44]. In order to address the multifaceted oral
delivery challenges, polymer-lipid systems have been developed with the aim of combining the
valuable features of both polymeric and lipid-based structures [33].
In a previous report, Eudragit and hyaluronan were combined with phospholipids to obtain
Eudragit-hyaluronan liposomes loaded with curcumin [39]. The association of Eudragit and
hyaluronan had a dramatic impact on the vesicles, facilitating their assembly and stability, along
with curcumin loading. The polymers, by interacting with each other and with the phospholipid,
were supposed to produce a network in which both the vesicles and curcumin were embedded and
stabilized, with a consequent improvement of the loading and retention of the polyphenol. Further,
the polymers favoured both the re-arrangement of vesicles upon rehydration of the freeze-dried
formulation with water and the re-dispersion of curcumin. The vesicles’ integrity was preserved
from the gastric environment and the local accumulation of curcumin in the intestines was promoted.
In another study, curcumin was incorporated in a novel vesicular carrier system, nutriosomes, made
of phospholipid and a water-soluble dextrin (Nutriose) [40], an association that improved vesicle
features, stability and performances in vitro and in vivo. Nutriose localized both in the inter-lamellar
and inter-vesicle media, leading to a stabilization of the vesicle structure. The dextrin acted also as a
cryo-protector, avoiding vesicle collapse during freeze-drying and as a protector against high ionic
strength and pH changes encountered in the gastrointestinal environment.
Int. J. Mol. Sci. 2018, 19, 1361 7 of 11
Although the combination of Eudragit with hyaluronan within phospholipid vesicles had been
described to increase their stability and promote curcumin deposition in the intestines, it was not able
to improve the systemic absorption of the polyphenol [39]. In agreement with this, we did not observe
an improvement of the in vivo antimalarial activity of curcumin loaded in Eudragit-hyaluronan
liposomes relative to the free compound. However, the important role of other glycosaminoglycans
(GAGs) related to hyaluronan as receptors of Plasmodium-infected red blood cells (for a review see [45])
suggests that this type of GAG-containing nanovectors can find relevant applications in treatments for
some of the most lethal pathological complications of malaria, such as sequestration in the placenta
and in the brain capillaries. As an example, the GAG chondroitin sulphate has been described as one
of the receptors in the placental sequestration of P. falciparum-infected red blood cells [46,47] and in
their cytoadherence to vascular endothelial cells lining the small blood vessels of the brain, leading
to their blockade in cerebral malaria [48,49]. A study reporting on the effect of polyethylene glycol
functionalization of nanoparticles on their intestinal transepithelial transport concluded that anionic
polymers are transported primarily through the paracellular route [50]. Given the anionic nature of
GAGs, their use in polymer-lipid vesicles holds promise for future orally administered treatments
against severe malaria.
We have shown that curcumin incorporated in Eudragit-nutriosomes significantly improved its
antimalarial activity upon oral administration to P. yoelii-infected mice. The superior performance of
Eudragit-nutriosomes versus Eudragit-hyaluronan liposomes could be reasonably explained by the
greater stability of the former, as indicated by the vesicle behaviour in gastrointestinal fluid studies.
A previous report also demonstrated that nutriosomes composed of P90G (160 mg/mL), curcumin
(10 mg/mL) and Nutriose (50 mg/mL) enhanced the accumulation of curcumin in the intestines and
the passage of the polyphenol through the intestinal mucosa, increasing its systemic bioavailability [40].
Curcumin has been proposed as an attractive partner for artemisinin, the main currently available
drug used to treat severe falciparum malaria. However, artemisinin plus curcumin liposomal
formulations have been only assayed for parenteral delivery [51], being oral intake the preferred
form of administration of antimalarial treatments for non-complicated malaria due to the poor basic
medical infrastructure of many endemic regions. This socioeconomic landscape of malaria, where
distribution networks for medicines often become disrupted, makes highly attractive a drug delivery
system like the one described here, which can be transported and stored in lyophilized form until its
use. Our results indicate that polymer-lipid vesicles are worth exploring for the future development of
orally administered curcumin-containing combination therapies against malaria.
4. Materials and Methods
4.1. Materials
Soy phosphatidylcholine (Phospholipon® 90G, P90G) was purchased from Lipoid GmbH
(Ludwigshafen, Germany). Low molecular weight hyaluronan (200–400 kDa) was purchased from DSM
Nutritional Products AG Branch Pentapharm (Aesch, Switzerland). Eudragit® S100 with molecular
weight about 125 kDa was provided by Evonik Industries AG (Darmstadt, Germany). Nutriose® FM06,
a soluble dextrin from maize, was kindly provided by Roquette (Lestrem, France). Curcumin, ethanol
and other reagents of analytical grade were purchased from Sigma-Aldrich (Milan, Italy).
4.2. Sample Preparation
The following curcumin-polymer dispersions were prepared: (A) curcumin (100 mg) and
hyaluronan (50 mg) in 10 mL of bidistilled water; (B) curcumin (100 mg) and Eudragit® S100 (500 mg)
in 10 mL of ethanol; (C) curcumin (100 mg) and Nutriose® FM06 (1000 mg) in 10 mL of bidistilled water.
All dispersions were stirred for 2 h at 25 ◦C. To produce Eudragit-hyaluronan liposomes, dispersion
A (1.5 mL) was mixed with dispersion B (0.5 mL), and 360 mg of P90G was added and sonicated
(45 cycles, 5 s on/2 s off, 13 µm probe amplitude) with a high intensity ultrasonic disintegrator
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(Soniprep 150, MSE Crowley, London, UK). To produce Eudragit nutriosomes, dispersion B (0.5 mL)
was mixed with dispersion C (1.5 mL); thereafter 360 mg of P90G was added and sonicated as above.
The resulting vesicle dispersions were frozen at −80 ◦C and freeze-dried for 24 h at −90 ◦C in a
FDU-8606 freeze-dryer (Operon, Gimpo, Korea). Each sample was rehydrated with 2 mL of water to
achieve a curcumin concentration of 10 mg/mL and sonicated (30 cycles, 5 s on/2 s off) prior to use.
The composition of the two formulations is reported in Table 1.
4.3. Vesicle Characterization
Vesicle formation and morphology were evaluated by cryo-TEM analysis. A thin film of each
sample was formed on a holey carbon grid and vitrified by plunging (kept at 100% humidity and room
temperature) into ethane maintained at its melting point, using a Vitrobot (FEI Company, Eindhoven,
The Netherlands). The vitreous films were transferred to a Tecnai F20 TEM (FEI Company) and the
samples were observed in a low dose mode. Images were acquired at 200 kV at a temperature ~−173 ◦C,
using low-dose imaging conditions with a CCD Eagle camera (FEI Company). The average diameter,
polydispersity index and zeta potential of vesicles were determined by dynamic and electrophoretic
light scattering using a Zetasizer nano-ZS equipment (Malvern Instruments, Worcestershire, UK) [52].
Prior to analysis, the samples were diluted with water (1:500). Non-incorporated curcumin was
removed by dialysis of 1 mL of rehydrated sample against water (2.5 L) using Spectra/Por® membranes
(12–14 kDa MW cut-off, 3 nm pore size; Spectrum Laboratories Inc., DG Breda, The Netherlands)
at 25 ◦C for 2 h, replacing water every 30 min. The amount of curcumin in each formulation was
determined after disruption of the vesicles with methanol (1:1000) by measuring A424 nm with a
UV/Vis spectrophotometer (Lambda 25, Perkin Elmer, Waltham, MA, USA). Entrapment efficiency (%)
is defined as the amount of curcumin found in dialysed formulations versus that found in non-dialysed
formulations. Hemolysis assays were done as described elsewhere [53].
4.4. Vesicle Behavior in Gastrointestinal Fluids
The average diameter, polydispersity index and zeta potential of Eudragit-hyaluronan liposomes
and Eudragit-nutriosomes were measured after dilution (1:500 v:v) at 25 and 37 ◦C and incubation at
pH 1.2 for 2 h and at pH 7.0 for 6 h, at 37 ◦C, in the presence of 0.3 M NaCl, which was used to increase
the ionic strength in the media.
4.5. In Vivo Antimalarial Activity Assay
The in vivo antimalarial activity of free and nanoformulated curcumin was analysed in a 4-day
blood suppressive test as described previously [54]. Briefly, BALB/c mice were inoculated 2 × 107
red blood cells from P. yoelii yoelii 17XL-infected mice by intraperitoneal injection. Treatment started
4 h later (day 0) with a single dose of 25 or 75 mg·kg−1·day−1 curcumin administered (in free form
or incorporated in vesicles) by a 150-µL oral delivery followed by identical dose administration for
the next 3 days. The samples were prepared at appropriate doses in phosphate-buffered saline (PBS)
and the control groups received PBS. Parasitemia was monitored daily by microscopic examination of
Giemsa-stained thin blood smears and antimalarial activity was calculated from day 3 by using the
Plasmoscore 1.3 software (Burnet Institute, Melbourne, Australia).
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